Airway Microbiota and Pathogen Abundance in Age-Stratified Cystic Fibrosis Patients by Cox, Michael J. et al.
Airway Microbiota and Pathogen Abundance in Age-
Stratified Cystic Fibrosis Patients
Michael J. Cox
1, Martin Allgaier
2¤a, Byron Taylor
2¤b, Marshall S. Baek
2, Yvonne J. Huang
1,5, Rebecca A.
Daly
3,4, Ulas Karaoz
3, Gary L. Andersen
3, Ronald Brown
2, Kei E. Fujimura
1, Brian Wu
1,6, Diem Tran
6,
Jonathan Koff
1,5, Mary Ellen Kleinhenz
1,5, Dennis Nielson
1,6, Eoin L. Brodie
3, Susan V. Lynch
1*
1Department of Medicine, University of California San Francisco, San Francisco, California, United States of America, 2Department of Anesthesia and Perioperative Care,
University of California San Francisco, San Francisco, California, United States of America, 3Ecology Department, Lawrence Berkeley National Laboratory, Berkeley,
California, United States of America, 4Department of Plant and Microbial Biology University of California, Berkeley, California, United States of America, 5Adult Cystic
Fibrosis Program, University of California San Francisco, San Francisco, California, United States of America, 6Pediatric Cystic Fibrosis Program, University of California San
Francisco, San Francisco, California, United States of America
Abstract
Bacterial communities in the airways of cystic fibrosis (CF) patients are, as in other ecological niches, influenced by
autogenic and allogenic factors. However, our understanding of microbial colonization in younger versus older CF airways
and the association with pulmonary function is rudimentary at best. Using a phylogenetic microarray, we examine the
airway microbiota in age stratified CF patients ranging from neonates (9 months) to adults (72 years). From a cohort of
clinically stable patients, we demonstrate that older CF patients who exhibit poorer pulmonary function possess more
uneven, phylogenetically-clustered airway communities, compared to younger patients. Using longitudinal samples
collected form a subset of these patients a pattern of initial bacterial community diversification was observed in younger
patients compared with a progressive loss of diversity over time in older patients. We describe in detail the distinct bacterial
community profiles associated with young and old CF patients with a particular focus on the differences between respective
‘‘early’’ and ‘‘late’’ colonizing organisms. Finally we assess the influence of Cystic Fibrosis Transmembrane Regulator (CFTR)
mutation on bacterial abundance and identify genotype-specific communities involving members of the Pseudomona-
daceae, Xanthomonadaceae, Moraxellaceae and Enterobacteriaceae amongst others. Data presented here provides insights
into the CF airway microbiota, including initial diversification events in younger patients and establishment of specialized
communities of pathogens associated with poor pulmonary function in older patient populations.
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Introduction
Chronic lung function decline, punctuated by recurrent airway
exacerbations is characteristic of CF pulmonary disease and
contributes substantially to patient morbidity and mortality [1].
Several culture-independent studies examining bacterial diversity
in a variety of human niches have demonstrated that shifts in
bacterial community composition underlie states of host health or
disease [2,3,4,5,6,7,8]. The advent of high-throughput technolo-
gies to examine microbial community composition permits high-
resolution profiling of organisms that are beneficial or detrimental
to the health of the human super-organism [9]. Recent studies
focusing on CF have demonstrated that bacterial assemblages, that
include a number of pathogens, exist in both adult and pediatric
airways [8,10,11,12,13,14,15,16]. These assemblages undoubtedly
contribute to the long-term lung function decline experienced by
CF patients, but the depth of bacterial diversity and the
relationship between airway microbiota and chronic pulmonary
disease observed in patients from birth through adulthood, is
currently unknown.
To perform an in-depth characterization of age-based bacterial
community composition of CF airways, independent deep-throat
swab and expectorated sputum samples from 51 pediatric and
adult patients respectively, were collected at the pediatric and
adult CF clinics at University of California, San Francisco.
Analysis was performed using the 16S rRNA PhyloChip, a high-
density, phylogenetic microarray, capable of identifying approx-
imately 8,500 bacterial taxa in parallel [17,18,19].
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Ethics Statement
The Committee on Human Research at University of
California San Francisco (UCSF) approved all study protocols,
and all patients or surrogates provided written, informed consent.
Sample collection
Airway samples from clinically stable adult and pediatric CF
patients, defined as having no change in pulmonary function for $2
months prior to sample collection were used for this study. Adult
sputum samples (n=37) were collected following routine spirometry
at the UCSF Adult Cystic Fibrosis Centre clinic. Samples were
mixed with approximately twice the volume of RNAlater (Ambion)
prior to nucleic acid extraction within 4 hours of collection.
Pediatric deep-throat swab samples (n=26) were collected at the
UCSF Pediatric Cystic Fibrosis Centre clinic from all patients (aged
up to 18 years), submerged in a sterile tube containing 3 ml of
RNALater prior to nucleic extraction within 4 hours of collection.
Deep-throat swabs were used as an alternative to sputum since the
majority of pediatric patients, particularly the younger individuals
are unable to produce sputum. The primary dataset for this study
comprised single, independent samples from 51 patients. To
determine the temporal changes in bacterial diversity within
patients of different age groups, a subset of 13 of these patients
from whom we had also collected a subsequent stable sample were
analyzed. Patient demographics are presented in Table S4.
Sample processing
Optimized DNA extraction protocols developed in-house using
CF sputum samples and representative Gram positive and Gram
negative bacteria were used for this study. Adult samples were
centrifuged for 10 minutes at 12,000 g and RNALater removed
prior to total genomic DNA extraction from 300 ml of sputum
(containing sputum plugs) using the Wizard Genomic DNA
extraction kit according to the manufacturer’s instructions (Pro-
mega, CA). Deep-throat swabs were added to lysis buffer from the
AllPrepDNA/RNA extraction kit(Qiagen,CA)ina lysing matrixB
tube (Qbiogene, CA) and lysed by bead-beating using a FastPrep
system (Qbiogene, CA) for 30 seconds at 5.5 m sec
21. Supernatant
was then transferred to the DNA column of the AllPrep kit and
nucleicacids extractedaccordingto the manufacturer’s instructions.
Universal primers 27F (59-AGAGTTTGAT CCTGGCTCAG-39)
and 1492R (59-GGTTACCTTGTTACGACTT-39) [20] were
used to amplify the 16S rRNA gene using 12 PCR reactions per
sample run across a gradient of annealing temperatures (48–58uC)
to maximize diversity recovered. PCR reactions contained 0.02
Uml
21 Takara Ex Taq DNA Polymerase (Takara Bio Inc Japan),
16 Takara buffer, 0.8 mM Takara dNTP mixture, 0.4 mg ml
21
bovine serum albumin (BSA) and 1.0 mM of each primer. PCR
conditions were 1 cycle of 3 min at 95uC followed by 25 cycles of
95uCfor30 s,the gradientannealingtemperaturefor30 s,72uCfor
2 min and a final extension at 72uC for 10 min. A total of 100 ng of
extracted DNA from adult sputum or pediatric deep-throat swab
samples was used per PCR reaction. Amplified products from all 12
annealing temperatures were pooled, gel-purified and processed for
PhyloChip analysis as previously reported [17], except that 250 ng
of each amplicon washybridized. As a negative control, nucleic acid
was extracted from sterile swabs and assayed for 16S rRNA product
as described above. No PCR product was detected.
Microarray analysis
A two-step normalization procedure was adopted to correct the
fluorescence intensities for amplicon target quantification variation
and in microarray technical variation. For analysis of bacterial
community composition we used the PhyloChip, a 16S rRNA
custom microarray developed at Lawrence Berkeley National
Laboratory and synthesized by Affymetrix Inc. (Santa Clara, CA,
USA). The array has 506,944 probes arranged in 712 rows and
columns representing approximately 8,500 bacterial taxa, with the
capability of detecting bacteria comprising at least 0.01% of a
population [21]. Each chip has additional probes that serve as the
following controls: (1) prokaryotic and eukaryotic metabolic genes
(added prior to fragmentation) to control for variations in
fragmentation, biotinylation, hybridization, washing, staining,
and scanning and (2) pre-labeled oligonucleotides added to the
hybridization mix to account for variation in hybridization,
washing, staining, and scanning. In addition, to minimize cross-
hybridization, at least eleven probe pairs (positive match and mis-
match oligonucleotides) are used to interrogate each taxon at at
least two discriminatory loci on the 16S rRNA gene. Combined
PCRs and control amplicons were fragmented to 50–200 bp using
DNase I (0.02 U mg
21 DNA; Invitrogen, USA) and One-Phor-All
buffer (NJ, USA). Biotin labeling was performed using terminal
deoxynucleotide transferase and ddUTP as per the manufacturer’s
instructions. The reactions were denatured at 99uC for 5 min and
hybridized to the PhyloChip for 16 hours at 48uC at 60 rpm. The
arrays were subsequently washed, stained and scanned as in [22].
Scanning of the arrays was performed using a GeneArray Scanner
(Affymetrix, CA, USA) and the intensity of all the probes was
treated as previously reported [17,19]. Positive probe pairs met
two criteria: (1) the fluorescence of the perfectly matched probe
was at least 1.3 times greater than the intensity of the control
(mismatch probe); (2) the value of the difference between perfectly
matched probe and mismatch probe intensities was at least 130
times greater than the squared noise value. The value of the
positive fraction (pf) was calculated for each probe set as the
number of positive probe pairs divided by the total number of
probe pairs in a probe set.
Data sets were conservatively filtered, with taxa determined as
present if pf $0.9 (90% of probes in a probe set for an individual
taxon) were positive. Changes in probe-set fluorescence intensity
are equivalent to changes in taxon relative abundance between
samples. Fluorescence intensity for every taxon determined to be
present in at least one sample was log transformed prior to analysis
using packages in the R statistical environment [23]. FastUnifrac
(Hamady et al, in review [24]) with branch length weighting by
taxon relative abundance (normalized log-transformed fluores-
cence intensity) was used to generate a phylogenetic distance
matrix from the PhyloChip data.
Quantitative PCR Validation
QuantitativePCR(Q-PCR)wasperformedonasubsetofsamples
with sufficient remaining DNA to validate the presence and relative
abundance of Pseudomonas spp., Staphylococcus spp., and Haemophilus
spp. using primers designed on the Greengenes 16S rRNA gene
alignment [22] using Arb [25] (Pseudomonas:9 0 5 6 a F5 9-CCGCA-
TACGTCCTGAGGGA GAAAGT-39, 9056aR 59-TCTCAGAC-
CAGTTACGGATCGTCGC-39; Staphylococcus:S a u r F 25 9-AACC-
CTTAAGCTTAGTTGCCATC-39,S a u r R 25 9-TTGACCTCG-
CGGTTTC GCTG-39; Haemophilus:H i n F5 9-AATGGCGTATA-
CAGAGGGAAG-39,H i n R5 9- CAATCCGGACTTAGACGTA-
CT-39). A total of 20 ng of DNA per reaction was used in triplicate,
25 ml Q-PCR reactions at an annealing temperature of 56uCw i t h
the Quantitect SYBR Green QPCR kit (Qiagen, MD) according to
the manufacturer’s instructions. Pearson’s correlation analysis of
inverse cycle threshold values against array fluorescence intensities
CF Airway Microbiota
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concordance between the two independent molecular methods.
In addition to Q-PCR validation, to confirm that specific
members of the community were truly present, a pair of primers
designed to detect Veillonella parvula (based on PhyloChip probes;
VDF59-CGTAATCAA CCTGCCCTTCAGAGG -39, VDR 59-
TTTCTGGCTTCC GAAGAAGAGGAAC-39) was used to
amplify a PCR product which was then submitted for bi-
directional sequencing. Sequence identity was assigned by
comparing reads to GenBank using NCBI’s BLAST (http://
blast.ncbi.nlm.nih.gov/).
Data analysis
From the FastUnifrac distance matrix the amount of variance
that each clinical variable e.g. sample collection method, age etc.
contributed to the dataset was calculated using the adonis function
of the vegan package in R [26]. Nearest-taxon index (NTI) and Net-
relatedness index (NRI) [27,28] measures of the phylogenetic-
relatedness of communities, were calculated using the picante
package in R [29]. NRI, is a standardized measure of the mean
pairwise phylogenetic distance of taxa in a sample, relative to a
phylogeny of an appropriate species pool, and quantifies overall
clustering of taxa on a tree. NTI, is a standardized measure of the
phylogenetic distance to the nearest taxon for each taxon in the
sample and quantifies the extent of terminal clustering, indepen-
dent of deep level clustering. A neighbor-joining with nearest-
neighbor interchange phylogenetic tree of representative 16S
rRNA sequences downloaded, pre-aligned from the Greengenes
database [22] was constructed using FastTree [30]. FastTree is a
neighbor-joining with nearest neighbor interchange phylogenetic
inference method using alignment profiles rather than distance
matrices. The topology of an initial neighbor-joining tree is
improved by rounds of nearest neighbor interchanges, which
recompute the profiles of each internal node. Splits in the tree that
result from this process are then tested by local bootstrapping to
see how well they are supported. This approach has the advantage
over alternative methods, of speed whilst approximating the
accuracy of character-based methods such as maximum-likeli-
hood, Bayesian analysis, or parsimony. This was used, together
with taxon richness, to calculate the mean phylogenetic distance
(MPD) and mean nearest phylogenetic taxon distance (MNTD)
using the phylogeny shuffle null model for each sample. MPD and
MNTD values were used, as previously described [27], to calculate
NRI and NTI values respectively for each sample. Inverse
Simpson’s diversity index [31], Pielou’s evenness [32] and
community richness were calculated using the vegan package in
R. To accurately reflect community richness for this calculation,
individual taxa were deemed to have an abundance of 0 if they did
not meet the pf $0.9 criterion. Temporal change in community
diversity was calculated by subtracting the calculated diversity
index of the second sample from the initial sample collected from
individual patients and normalized by dividing the result by the
number of days between sample collections to provide the change
in diversity over time.
Linear regression analysis was performed using calculated
metrics of community composition and patient variables e.g.
age, CFTR mutation etc. in Statplus (Analystsoft, Vancouver,
Canada). Correlation analysis of each individual taxon abundance
against patient age or CFTR mutation was performed using the
multtest package [33] available as part of the Bioconductor suite of
analysis programs [34]. P-values were adjusted for false discovery
using the Benjamini-Hochberg procedure [35] or q-value method
[36] where applicable. A phylogenetic tree of taxa that
significantly positively or negatively correlated with age was
constructed using FastTree as described above. Samples were
assigned to age bins of 5 years (all bins contained $3 samples) and
taxon fluorescence values in each bin were averaged and scaled
relative to the highest value in the overall dataset. The tree
illustrating these changes was imported to the Interactive Tree of
Life (http://itol.embl.de/; [37]) and annotated. Taxa that were
identified by Bellerophon [38] running on the Greengenes
database as chimeric or those taxa represented by sequences of
less than 600bp were not reported.
Results
Relationship between Pulmonary Function and Airway
Bacterial Diversity
Sample type (deep throat swab or sputum) explained only 7% of
community variance (p=0.001), with age group explaining 33%
(p=0.001), suggesting that the method of sample collection did not
substantially impact community compositional differences, al-
though differences in the site of sample collection likely explains
this low level of variance observed. Between 78 and 1012 taxa
were detected in the samples and 1,837 different taxa (defined as
species or strains that share$97% 16S rRNA sequence identity)
were detected in the entire cohort, which represents substantially
greater bacterial richness than previously reported using other
culture-independent methods [10,11]. This is likely due to the
ability of the PhyloChip to detect members that represent as little
as 0.01% of the community in parallel with highly abundant taxa
[18]. This aspect of array analysis is particularly advantageous
when analyzing CF airway samples that tend to be dominated by a
small number of highly abundant species [10]. However due to the
potential for cross-hybridization at the taxon-level, the majority of
our subsequent analyses was performed at higher levels of
classification. These taxa belonged to 43 phyla with the majority
belonging to the phyla Actinobacteria, Bacteroidetes, Firmicutes
and Proteobacteria with smaller numbers belonging to the
Acidobacteria, Planctomycetes and Spirochaetes (a complete list
of all taxa detected is provided in Supplementary Table S1).
Known CF pathogens, routinely cultured from CF sputum, were
detected in the samples. S. aureus could be detected in 65% of
samples (61% of adult samples, 72% of pediatric) and P. aeruginosa
in 73% of samples (91% of adult samples, 39% of pediatric). A
subset of 14 adult CF samples was used to examine the abundance
of three organisms by Q-PCR. Correlation analysis of Q-PCR
data with PhyloChip fluorescence intensity demonstrated good
concordance for P. aeruginosa (otu_9056; r=0.76; p#0.001), S.
aureus (otu_3258; r=0.86; p#0.0001) and H. influenzae (otu_8555;
r=0.56; p=0.002). Although multiple safeguards are in place to
minimize cross-hybridization, the PhyloChip, like all other culture-
independent profiling technologies is susceptible to false positives.
Therefore, targeted PCR amplification using primers designed on
probes for OTU 940, whose representative species is Veillonella
parvula was used to amplify a PCR product which was then
sequenced. Sequence analysis demonstrated that the sequence
exhibited 99% homology with Veillonella parvula across 631 nt.
To determine whether a linear relationship existed between
patient age and pulmonary function (forced expiration volume in
one second [FEV1% predicted]), we tested for correlation between
these variables, for samples where FEV1 measurements were
available (n=44). Despite the absence of standardized airway
function testing for the very young pediatric patients (age #5,
n=7) the data confirmed that older patients CF patients exhibited
significantly lower pulmonary function (r=20.48; p,0.0003;
Fig. 1A). To determine whether age-related pulmonary function
was associated with aspects of the airway bacterial community
CF Airway Microbiota
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patient age (n=51) and taxonomic richness (number of bacterial
taxa detected), community evenness (relative distribution of taxa
within communities), taxonomic diversity (metric based on both
richness and evenness) and phylogenetic relatedness; Net Relat-
edness Index (NRI) and Nearest Taxon Index (NTI), two indices
that measure the degree of phylogenetic clustering or dispersion
within communities [39]. These analyses revealed that older CF
patients possessed airway bacterial communities that were less rich
(r=20.35, p,0.001), less even (r=20.38, p,0.0006) and had
significantly lower bacterial diversity (r=20.33, p,0.004;
Table 1). In addition, bacteria in the airway communities of older
patients were more related to each other (NTI, r=0.47,
p,0.0001; NRI, r=0.35, p,0.0001; Table 1; Fig. 1B and C)
with the NTI and NRI indicating significant phylogenetic
clustering of the taxa in these samples at both the terminal
branches (taxon level) and at higher phylogenetic levels (family,
class etc.). These data demonstrate that compared to younger CF
patients, older individuals exhibit reduced airway bacterial
diversity and assemblages of more closely-related organisms which
occurs in parallel with age-related pulmonary function decline,
implicating this structural shift in community composition in the
pathophysiology of late stage CF airway disease. This has not
previously been demonstrated in an age-stratified cohort spanning
neonates to adults.
Airway Bacterial Diversity and CFTR Genotype
Our cohort consisted of a variety of CFTR genotypes,
permitting the opportunity to examine the relationship between
mutation and community composition. Patients were classified in
3 groups: homozygous-DF508 (n=19), heterozygous-DF508
(n=19) or non-DF508 mutation (n=13). To determine which
aspects of community composition were most related to mutation-
specific loss of pulmonary function, regression analyses against
community metrics and bacterial taxon abundance were per-
formed. Significant negative correlations between patient age and
bacterial diversity, richness and NTI (Table 1) were identified for
the homozygous-DF508 group. Compared with younger patients,
community restructuring in older homozygous-DF508 patients was
primarily due to loss of multiple members of the Mycobacteria-
ceae, Staphylococcaceae, Enterobacteriaceae, Acholeplasmata-
ceae, Pasteurellaceae and Chlamydiaceae; older individuals were
primarily associated with higher abundance of members of the
Pseudomonadaceae (Supplementary Table S2). Compared to
younger heterozygous-DF508 and non-DF508 patients, older
individuals with these genotypes did not exhibit significant
reductions in taxonomic richness, evenness or diversity’’
(Table 1); however, for both groups, these patients did exhibit
increased NTI and NRI of their airway communities (Table 1).
Similar to the homozygous patients, the older heterozygous-DF508
patients also exhibited increased abundance of members of the
Pseudomonadaceae and Xanthomonadaceae; in addition, they
also exhibited significant increases in the Moraxellaceae, and
Sphingomonadaceae. In contrast to DF508 patients, non-DF508
subjects did not exhibit an age-based positive correlation with the
Pseudomonadaceae or with any other bacterial family. Instead
younger patients were strongly associated with multiple members
of the Enterobacteriaceae, Campylobacteraceae and Helicobac-
teraceae (Supplementary Table S2). These families appear to be
specifically associated with the non-DF508 group, as they did not
feature prominently in heterozygous-DF508 or homozygous-
DF508 airways.
Temporal Diversity Changes
The temporal change in bacterial diversity of a subset of 13
patients ranging from 9 months to 43 years for whom a second,
subsequent clinically stable airway sample was available was
examined. All pediatric patients examined up to 11 years of age
(n=10) exhibited a net increase in bacterial diversity over time. In
contrast a net decrease in community diversity was observed for
older patients (n=3; Fig. S1), suggesting that CF patients exhibit
an initial expansion of airway diversity (colonization and
diversification period) over the first decade of life, after which a
progressive decline in diversity and development of increasingly
phylogenetically-related consortia occurs (establishment of com-
petitively dominant species). However, while provocative, given
the small number of patients and samples analyzed for this section
of the study, this data should be interpreted cautiously. An
expanded study with substantially more temporal samples coupled
with extensive medical histories for these patients is necessary to
confirm that this observation holds true in larger populations over
more protracted time-frames and if so, to determine the factors
Figure 1. Patient age is related to pulmonary function and
aspects of community relatedness. Boxplots with age bins
containing three or more samples are displayed; Relationships between
patient age and (A) pulmonary function (B) Net Relatedness Index and
(C) Nearest Taxon Index are illustrated. As pulmonary function declines,
increasing phylogenetic relatedness at both the deeper levels and
terminal branches of the phylogenetic tree respectively is evident.
doi:10.1371/journal.pone.0011044.g001
CF Airway Microbiota
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administration.
These shifts in community structure and diversity observed in
older CF patients may contribute to the phenomenon of age-
specific airway pathogen abundance in CF patients [40,41]. To
examine these relationships in more detail, correlations between
the abundance of all known CF airway pathogens and patient age
were determined to identify CF pulmonary disease pathogens
associated with pediatric and adult CF patients respectively. Of the
known CF pathogens, only Haemophilus influenzae (p=0.02,
r=20.31), Stenotrophomonas maltophilia (p=0.02, r=0.31) and
Pseudomonas aeruginosa (p=0.001, r=0.42) exhibited significant
correlations with age (Table 2). P. aeruginosa and S. maltophilia
abundance was greatest in older CF patients (Fig. 2), who
exhibited lower bacterial diversity. In contrast, H. influenzae
exhibited the opposite trend with a peak in abundance in younger
patients when community diversity was greatest (Fig. 2), observa-
tions, which are supported by previous culture-based reports
[41,42,43].
An advantage of the array is the ability to detect taxa not
normally isolated by conventional culture. Thus the PhyloChip
data was analyzed to identify other bacterial species that exhibited
age-related changes in abundance, in an attempt to more broadly
define those organisms associated with pediatric and adult CF
airways. Following false discovery adjustment, a total of 113 taxa
exhibited a significant correlation with age; 45 were positive
correlations, 68 negative (a complete list is provided in
Supplementary Table S3). Of the 45 taxa significantly positively
correlated with age, almost half (22 taxa) were members of the
Pseudomonadaceae (Fig. 2). This confirmed our previous
observation that older CF patients possess airway communities
that are less diverse and more phylogenetically related. Whether
this phenomenon is a result of the Pseudomonadaceae actively
defining a niche with less diversity or is due to their exploitation of
an existing low diversity niche is unknown.
Many of the bacteria identified in this analysis have not yet been
phenotyped, nor their potential for pathogenesis assessed.
However, a number of known pathogens were more prevalent
in younger CF patients, including members of the Mycobacteri-
aceae [44] and obligate intracellular members of the Chlamyd-
iaceae [45,46] and the Mycoplasmataceae [47] (Supplementary
Table S3). In contrast, known or potential pathogens associated
with older CF patients included members of the Burkholderiaceae
and Thermoactinomycetaceae [48,49]. Age-based relationships
with anaerobic species were also examined since their relevance to
CF airway disease is a subject of much recent research and
discussion [50,51]. Of the strict anaerobic bacteria that had a
significant correlation with age, the majority exhibited a negative
relationship and were detected in higher abundance in younger
patients (Supplementary Table S3). However, a very small number
of Clostridia and sulfate-reducing species exhibited an increase in
relative abundance in older CF patients.
Discussion
In this study, CF patient airway colonization was examined
using a culture-independent phylogenetic microarray and samples
from a cohort of patients defined as clinically stable (no change in
pulmonary function for $2 months prior to sample collection),
aged between 9 months and 72 years (Table S4). For the purpose
of this study it was important to consider only clinically stable time
points to determine the longer-term evolution of the CF airway
microbiota and avoid the pronounced short-term impact of
pulmonary exacerbation and antimicrobial therapy. Deep throat
swabs were used to sample pediatric patients in this study, this was
to ensure inclusion of neonatal and younger pediatric patients who
do not produce sputum. Expectorated sputum samples (following
routine spirometry) were collected for adult patients. Despite
differences in sampling between the age groups, the mode of
sampling did not seem to drive the bacterial community
composition. One caveat of airway studies is the necessity to
collect the samples through the oral cavity and hence the potential
for sample contamination. Both deep throat swab and sputum
samples are routinely used for clinical laboratory culture to guide
antimicrobial treatment regimes for CF patients. In addition,
Rogers and colleagues have previously demonstrated that distinct
bacterial communities exists in oral and sputum CF samples [14],
also supporting the hypothesis that oral contamination minimally
impacts the assessment of airway samples from CF patients.
A total of 158 bacterial families were detected in these samples,
the majority of taxa detected in these families have not been
previously associated with cystic fibrosis. There are several
potential explanations for this including that the PhyloChip is a
highly sensitive molecular assay, capable of detecting organisms
Table 1. Relationship between CF patient age and metrics of bacterial community composition.
Analysis All clinically stable Homo-DF508 Hetero-DF508 Non-DF508
Age vs Richness 20.35
a p
b,0.001 0.53 p,0.02 0.007 p,0.98 0.36 p,0.25
Age vs Evenness 20.38 p,0.0006 0.08 p,0.75 0.32 p,0.12 0.35 p,0.27
Age vs Diversity 20.33 p,0.004 0.53 p,0.02 0.0005 p,0.99 0.35 p,0.27
Age vs NRI 0.47 p,0.0001 0.37 p,0.13 0.63 p,0.005 0.62 p,0.03
Age vs NTI 0.52 p,0.0001 0.56 p,0.01 0.26 p,0.31 0.74 p,0.006
aR values.
bP values ,0.05 are considered significant.
doi:10.1371/journal.pone.0011044.t001
Table 2. Correlation between pathogen abundance and
increasing CF patient age.
Pathogen R p-value
Haemophilus influenzae 20.31 0.02
Pseudomonas aeruginosa 0.42 0.001
Stenotrophomonas maltophilia
(Xanthomonas axonopodis)
0.31 0.02
Shaded pathogens exhibit a significant correlation.
doi:10.1371/journal.pone.0011044.t002
CF Airway Microbiota
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Validation by sequence analysis of Veillonella parvula confirms its
reported presence in this niche by the array, suggesting that
multiple organisms may co-habit this niche. Indeed, other culture-
independent T-RFLP-based studies (estimated by the authors as
having a sensitivity of 1% of the population), clone library
sequencing and temporal temperature gradient gel electrophoresis
(TTGE) have also detected a number of species that had not
previously been associated with CF airways [10,11,15,16]. Even
with the limitations of culture-based methods, previous studies
have also demonstrated the presence of uncharacteristic species in
CF airways using this approach [52]. More recently a sequence-
based study of a CF patient airway sample revealed the presence of
multiple unusual species not previously reported in this niche such
as Dolosigranulosum pigrum, Kocuria rosea, Granulicatella spp. and
Bergeyella spp. amongst others [53]. All of the reported species
detected in this sequence-based study were also detected by
PhyloChip in several of the patients in our study. This in addition
to our sequence-based validation, collectively suggest that a
multitude of bacterial species do indeed exist in CF airway
samples and underscore the need to perform truly deep
sequencing to overcome the issue of the dominant species present
and detect the ‘‘rare biosphere’’ present.
The impact of sequence depth on interpretation of results was
recently demonstrated by Qin et al [54], in a large-scale sequence-
based human microbiome study of 124 European individuals.
Increasing the sequence depth coverage for samples from two
individuals (from ,4G bt o.8.5 Gb) resulted in an increase in the
number of strains common to these two individuals by 25% [54].
This demonstrates that human host microbiota are intrinsically
diverse and that our current view of these assemblages is only
curtailed by the limited depth of sequencing that has been used to
Figure 2. Phylogenetic tree displaying relationship between patient age and taxon abundance. Taxa exhibiting a significant increase
(red) or decrease (blue) in relative abundance with increasing CF patient age are illustrated. Scale bar indicates 0.01 nucleotide substitutions per base.
doi:10.1371/journal.pone.0011044.g002
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technology used in this study is potentially subject to cross-
hybridization at the taxon-level, it nonetheless provides a
standardized tool for high-resolution profiling of samples,
permitting detection of low abundance species in dominated
communities and relative changes in community composition that
can be related to clinical measurements and features of the disease.
In natural systems, colonizing populations are observed to
develop progressively, typically leading to increased biomass,
productivity and diversity [55,56,57,58]. This has recently been
exemplified in the human gastrointestinal tract; initial colonization
by pioneer aerobic species is followed by facultative anaerobes and
finally strict anaerobes, concomitant with an increase in bacterial
biomass and productivity characteristic of the stable adult
microbiota [59]. Though this is a cross-sectional study, data
presented here provides insights into the progression of CF airway
colonization. Evidence for initial diversification in younger
patients, decreases in diversity in older patients and the presence
of specialized communities of phylogenetically related species
(Fig. 3) associated with poor pulmonary function in these older
patient suggest that CF airway microbiota may also follow the
rules of community assembly previously reported at other host
niches. This form of colonization involving an initial rapid rise in
species diversity as successive invasions occur, followed by species
replacement as the community develops is common, and has
previously been reported for other ecosystems and at higher
trophic levels [60,61,62]. Once established, severe antimicrobial-
based perturbation of microbial communities has been shown to
lead to long-term changes in community composition and a loss of
diversity in animal models [63]. Subsets of older CF patients
exhibit diminished improvement in lung function in response to
antimicrobial administration compared with younger CF patients
[64], who also typically exhibit better pulmonary function. This
suggests that the more phylogenetically-related microbial assem-
blages detected in older CF patients may be more resistant to these
antimicrobials and contribute to poorer airway function, while the
more diverse pediatric microbial assemblage is more sensitive to
antimicrobial perturbation and linked to improved pulmonary
function. More recently a study has demonstrated a ‘‘like begets
like’’ phenomenon, in that colonization of a specific niche by
particular keystone species results in ‘‘invasion’’ of that community
by other phylogenetically related species [65]. It appears from our
data that a similar scenario exists in older CF patients whose
airway microbiota exhibits phylogenetically related members and
is largely composed of Pseudomonadaceae. That multiple
members of the Pseudomonadaceae may co-exist in CF airways
is not unprecedented, Harris and colleagues have previously
demonstrated with relatively shallow sequencing depth, the
presence of other Pseudomonas species other than P. aeruginosa, in
50% of their CF patient airways [10], suggesting that multiple
members of the Pseudomonadaecaeae may co-exist in this niche.
It seems counter-intuitive that a greater diversity of organisms
(in younger CF patients) would be associated with better lung
function, however several studies have demonstrated that dramatic
changes in community structure through loss of diversity as
reported here, are increasingly being associated with chronic
inflammatory diseases, pathogen outgrowth and poor clinical
outcome [3,66,67,68,69]. It appears therefore, that bacterial
community structure and composition represents an important
factor in defining the functionality of the microbial assemblage and
host health status. However analysis of CF cohorts is difficult and
confounded by the fact that a number of the older patients in this
study have less severe disease, which may be associated with their
microbial community composition or different treatment regi-
mens. In addition, there is also the possibility that the findings
reported here are due to other factors that track with age such as
antibiotic use, chest physical therapy, adherence, nutrition or
other factors. Nonetheless, this study demonstrates that distinct
microbial assemblages are associated with CF patient age and that
community composition is correlated with CF genotype and
aspects of pulmonary disease in this patient population.
This study also provided information on the relationship
between CFTR mutation and the airway microbiota. It has
previously been reported that CFTR mutation changes the airway
microenvironment [70,71,72], which would presumably influence
the microbial community that establishes in this niche. A strong
relationship between DF508 CFTR mutation and absence of
multiple members of the Mycobacteriaceae, Staphylococcaceae,
Enterobacteriaceae amongst others with a concomitant rise in
abundance of members of the Pseudomonadaceae was identified
in older CF patients with this genotype. This suggests that
mutations rendering the CFTR non-functional are associated with
Figure 3. Bacterial community structure and composition associated with CF patient age. Compared to pediatric communities, adult CF
patient airway communities exhibit lower bacterial diversity and are more uneven. Increased diversity in younger airways is correlated with a large
number of known pathogenic families. Loss of diversity in older airways is strongly correlated with loss of pulmonary function and emergence of
competitively dominant species such as members of the Pseudomonadacece, Burkholderiaceae and Xanthomonadaceae. For simplicity, the initial
increase in diversity exhibited by younger CF patients is not illustrated.
doi:10.1371/journal.pone.0011044.g003
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outgrowth of a small group of phylogenetically-related species as
these patients age. Whether this is directly related to the severity of
the mutation and the creation of a distinct niche due to lack of
functional CFTR or due to the treatments necessary to manage
these patients (or a combination of both) is unclear. However,
patients with heterozygous DF508 or non-DF508 mutations also
exhibited distinct pathogen profiles. Older heterozygous DF508CF
patient airways were associated with Moraxellaceaea and
Sphingobacteriaceae, two bacterial families that have recently
been associated with chronic obstructive pulmonary disease [73]
and invariant Natural Killer T cell induction in asthmatic mice
[74]. While non-DF508 patients were associated with a relatively
less severe pathogen profile. This study, albeit small, demonstrates
that homozygous-DF508 mutation is associated with the most
substantial change in airway community structure and phylogeny
in older patients. Furthermore, particular CFTR mutations, which
are known to influence the airway environment [70,71,72], are
associated with distinct pathogen profiles, a finding that may
explain the range of severity in pulmonary symptoms commonly
observed with various CFTR genotypes, and has implications for
patient-tailored care [75].
It is important to note that detailed functional analyses of
longitudinal CF airway samples are necessary to comprehensively
determine the impact of treatment on the airway microbiota.
Given our data, it appears that older CF patients possess a stable
core of pathogenic organisms which presumably are selected for
over time due to repeated antimicrobial pressure. With the
increasing lifespan of CF patients due to successful disease
management, understanding the long-term impact of antimicro-
bials on the CF microbiota may lead to further improvements in
treatment strategies and life expectancy. Novel approaches that
involve manipulation of microbial consortia, rather than destruc-
tion of the community structure may offer an alternative
therapeutic approach for patient-tailored management of chronic
airway disease. This concept is gaining increasing support [8,63]
and there is evidence for its efficacy, although the mechanism
underlying these benefits remains unclear. A recent pilot study of
pediatric CF patients supplemented with a probiotic Lactobacillus
species or placebo demonstrated that in addition to reduced
gastrointestinal inflammation, patients who received the probiotic
species exhibited a significant reduction in hospitalizations for
pulmonary exacerbation [76]. Certainly with the advent of
newborn screening programs and sophisticated culture-indepen-
dent tools to comprehensively monitor patient airways, the
opportunity to intervene at a very early age and alter the course
of airway microbial colonization to improve patient outcome is
unprecedented.
The CF microbiota is a complex community, but the use of
molecular ecological approaches permits the progression of CF
airway disease to be comprehensively explored. This work
provides the foundation for an improved understanding of
polymicrobial CF airway colonization, the relationship between
community structure, composition and lung function in CF
patients and the influence of CFTR mutation on the airway
microbiota. Antibiotic administration, the acquisition of organisms
from the internal and external environments, and changes
associated with patient age (increased lung surface area, hormonal
changes) represent key influences on this ecosystem. Understand-
ing the mechanistic relationship between community dynamics,
pathogen abundance and behavior, and the host immune response
is crucial to further extending the lifespan of this patient
population.
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